Management of Resectable Pancreatic Cancer

Video

This video examines the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Davendra Sohal, MD, MPH, of the Cleveland Clinic in Cleveland, Ohio, discusses the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.

      Sohal spoke on this topic during an education session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

      Recent Videos
      Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
      Genetic Data May Inform Personalized Radiotherapy Strategies for Cancer Care
      Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
      Molecular Diagnostics, PIPAC Appear "Exciting" in GI Cancer Surgical Care
      Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
      Prospective Study May Clarify PTEG Benefits in Malignant Bowel Obstruction
      Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
      PTEG Elicits Encouraging Technical Outcomes in Malignant Bowel Obstruction
      Data Show Underutilization of Appendectomy in Appendix Cancer Population
      Data Show Underutilization of Appendectomy in Appendix Cancer Population
      Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
      Novel Treatments May Have the Potential to Impact GI Cancer Care
      Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
      Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Staged Colectomy May Be Preferable to Upfront Colectomy in Appendix Cancer
      Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
      CRC Yields Most Prevalent Data at Recent GI Meeting
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      No Subgroups Benefit From HIPEC/CRS in Colorectal Peritoneal Metastasis
      Related Content
      Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen responded.

      Avutometinib/Defactinib Combo May Elicit Efficacy in Metastatic PDAC

      Roman Fabbricatore
      May 27th 2025
      Article

      Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen had a response.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

      ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

      Russ Conroy
      May 23rd 2025
      Article

      From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

      A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

      Managing Risks, Planning Treatment, & Making Progress in Pancreatic Cancer

      Kelley A. Rone, DNP, RN, AGNP-c
      December 2nd 2024
      Podcast

      A nurse practitioner discussed risk factors, diagnostic challenges, and treatment planning in patients with pancreatic cancers.

      Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.

      Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer

      Roman Fabbricatore
      May 19th 2025
      Article

      Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.

      For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

      Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC

      Roman Fabbricatore
      May 19th 2025
      Article

      For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.